Literature DB >> 21160929

A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.

Tristan D Yan1, Christopher Qian Cao, Stine Munkholm-Larsen.   

Abstract

Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown to be of benefit for treating selected patients with peritoneal surface malignancy. It has become a new standard of care in the management of diffuse malignant peritoneal mesothelioma and peritoneal dissemination of appendiceal malignancy. Numerous recent publications on carcinomatosis from colorectal cancer and gastric cancer identify groups of patients that would benefit from this local-regional approach for prevention and treatment of carcinomatosis. This review focuses on pharmacological information regarding intraperitoneal chemotherapeutic agents commonly used in gastrointestinal oncology.

Entities:  

Keywords:  Cisplatin 5-fluorouracil; Doxorubicin; Intraperitoneal chemotherapy; Mitomycin C; Paclitaxel; Peritoneal surface

Year:  2010        PMID： 21160929      PMCID： PMC2999163          DOI： 10.4251/wjgo.v2.i2.109

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  50 in total

1.  Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.

Authors:  O Glehen; D Osinsky; E Cotte; F Kwiatkowski; G Freyer; S Isaac; V Trillet-Lenoir; A C Sayag-Beaujard; Y François; J Vignal; F N Gilly
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

2.  A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery.

Authors:  F Mohamed; P Marchettini; O A Stuart; D Yoo; P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2003-04       Impact factor: 4.424

Review 3.  Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis.

Authors:  A D Stephens; J F Belliveau; P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996

4.  Potential for therapy of drugs and hyperthermia.

Authors:  G M Hahn
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies.

Authors:  T Fujimura; Y Yonemura; H Fujita; Y Michiwa; T Kawamura; N Nojima; T Sato; S Fushida; G Nishimura; K Miwa; I Miyazaki; K Murakami; K Katayama; A Yamaguchi
Journal:  Int Surg       Date:  1999 Jan-Mar

Review 6.  The systemic administration of intravenous melphalan.

Authors:  G Sarosy; B Leyland-Jones; P Soochan; B D Cheson
Journal:  J Clin Oncol       Date:  1988-11       Impact factor: 44.544

Review 7.  For the clinical application of thermochemotherapy given at mild temperatures.

Authors:  M Urano; M Kuroda; Y Nishimura
Journal:  Int J Hyperthermia       Date:  1999 Mar-Apr       Impact factor: 3.914

8.  Determinants of paclitaxel penetration and accumulation in human solid tumor.

Authors:  H J Kuh; S H Jang; M G Wientjes; J R Weaver; J L Au
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

9.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

Authors:  Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 10.  Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma.

Authors:  P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996
View more
  37 in total

1.  Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment.

Authors:  Vaidotas Cesna; Arturas Sukovas; Aldona Jasukaitiene; Giedre Silkuniene; Saulius Paskauskas; Zilvinas Dambrauskas; Antanas Gulbinas
Journal:  Oncol Lett       Date:  2019-06-18       Impact factor: 2.967

Review 2.  A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement.

Authors:  Maneesh K Beeharry; Wen-Tao Liu; Xue-Xin Yao; Min Yan; Zheng-Gang Zhu
Journal:  Transl Gastroenterol Hepatol       Date:  2016-10-20

Review 3.  Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.

Authors:  Daisuke Kobayashi; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2016-11-01       Impact factor: 7.370

4.  Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.

Authors:  Yue Zhu; Nader Hanna; Cherif Boutros; H Richard Alexander
Journal:  J Gastrointest Oncol       Date:  2013-03

5.  Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites.

Authors:  Xuefeng Ni; Ping Wu; Jun Wu; Mei Ji; Bo Tian; Zhenxing Jiang; Yue Sun; Xiaoxiao Xing; Jingting Jiang; Changping Wu
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

6.  A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.

Authors:  Stephen K Williamson; Gary A Johnson; Holly A Maulhardt; Kathleen M Moore; D S McMeekin; Thomas K Schulz; Gregory A Reed; Katherine F Roby; Christine B Mackay; Holly J Smith; Scott J Weir; Jo A Wick; Maurie Markman; Gere S diZerega; Michael J Baltezor; Jahna Espinosa; Charles J Decedue
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-23       Impact factor: 3.333

Review 7.  Intraperitoneal chemotherapy for locally advanced gastric cancer to prevent and treat peritoneal carcinomatosis.

Authors:  Han Liang
Journal:  Transl Gastroenterol Hepatol       Date:  2016-08-09

Review 8.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

Review 9.  Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.

Authors:  Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-09

10.  Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

Authors:  Rong Liu; Aaron H Colby; Denis Gilmore; Morgan Schulz; Jialiu Zeng; Robert F Padera; Orian Shirihai; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.